
In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, offers guidance for female medical researchers who are faced with a declining number of female colleagues in the workforce.

Kelan Thomas, PharmD, MS, discussed potential adverse effects and drug-drug interactions that pharmacists should be aware of with psychedelic medicines.

Pilocarpine (Vuity) is a cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults.

PinkEye Relief are sterile eye drops that temporarily relieve burning, swelling, and crusting.

The CIC is a combination of Novavax’s COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate.

Each time a pharmacist immunizes a patient against one of the 27 infections for which a safe and effective vaccine exists, the profession continues to protect communities against diseases that wreaked havoc on generations.

The application is based on positive results from the ASCEND phase 3 clinical trial, assessing the efficacy and safety of daprodustat for the treatment of anemia from chronic kidney disease.

Evusheld has been found to significantly reduce the risk of developing symptomatic COVID-19.

The updated efficacy analyses showed that tislelizumab in combination with chemotherapy continued to demonstrate a clinically significant progression-free survival benefit for individuals with recurrent or metastatic nasopharyngeal cancer.

With additional responsibilities and a wider scope of services comes the need for more effective and efficient delegation.

The analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Analysis indicates that quitting provides roughly the same benefit as taking 3 medications together.

The agent is the first oral therapy for this indication.

Investigational CAR T-cell therapy is currently being evaluated in an ongoing dose escalation phase 1 trial to analyze its safety and tolerability in treating non-Hodgkin lymphoma.

US segment to hit $121.8 billion in 2022, notes market research firm.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses where she sees the classification of lymphoma progressing in the coming years.

Among Black and Latina women with heart failure, negative health outcomes are magnified due to significant health disparities and inequities in the management of the chronic condition.

Fosdenopterin (Nulibry) is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A.

Premsyn PMS temporarily relieves symptoms associated with premenstrual syndrome.

Proactive retention strategies can improve employee satisfaction and reduce turnover rates.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discusses what biosimilars in the pipeline are expected to launch this year.

Asthma contributed most to the risk of high blood pressure and coronary heart disease.

Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks.

Analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Although the ISMP created the guidelines for hospitals, they are applicable in other health care settings.

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Additionally, the safety profile in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified.